Radiation-Induced Breast Angiosacoma: A Case Report

A. Arfa¹*, D. Van Gestel², A. Benider³

¹Departement of Radiation Oncology, Institute Jules Bordet, Boulevard de Waterloo 121, 1000 Bruxelles, Belgium
²Professor, Department of Radiation Oncology, Chu ibn Rochd Pavillon 40, Casablanca, Morocco

DOIs: 10.36347/sjmc2020.v08i07.012 | Received: 15.07.2020 | Accepted: 23.07.2020 | Published: 24.07.2020

*Corresponding author: A. Arfa

Abstract

Breast angiosarcoma is a rare conjunctival tumor of vascular endothelial origin, primary in young patients, radio-induced in the elderly, characterized by its malignancy and by its polymorphic clinical and radiological presentation; it has a very poor prognosis, the frequent occurrence of visceral metastases and rapid recurrence. We report a case of breast angiosarcoma, in a 56 year old patient, with a history of breast cancer, treated by conservative surgery and adjuvant radiotherapy. We will discuss through this observation, the epidemiological, diagnostic and therapeutic aspects of this type of rare aggressive tumors.

Keywords: Angiosacoma, breast, radio-induced, clinic, treatment.

Copyright @ 2020: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

The breast angiosarcoma is a rare connective malignancy of vascular origin. It occurs either spontaneously, with no obvious trigger for younger women (30-40), or after irradiation as part of conservative treatment for breast cancer for older women [1-6].

It is characterized by a strong malignancy of which the evolution is towards rapid recurrence and the appearance of visceral metastases. Its histological diagnosis is based on a rigorous analysis of the pieces of excision [7-10].

We report the observation of radiation-induced angiosarcoma in a 43-year-old patient who received conservative treatment for breast cancer 6 years ago.

We will discuss the epidemiological, diagnostic, therapeutic and progressive aspects of this type of tumor.

OBSERVATION

Mme T. M, 68 years old, followed since November 2014 for IDC of the right breast cT2N1M0 luminal B, Fish amplified.

The patient received 8 standard neo-adjuvant chemotherapy courses (4 EC cycles then 4 Taxol cycles) associated with herceptin.

The patient benefited in April 2015 of a tumorectomy and an axillary recess then reconstruction by oncoplasty with pathology (stage ypT1bN0).

Then our patient had benefited from a local treatment based on adjuvant radiotherapy on the right breast and the right supraclavicular ganglion areas at a dose of 40.05 Gy according to a hypofractionated radiation with a boost of 15 Gy at the level of the tumor bed. Anti-aromatase hormone therapy was prescribed, due to the positivity of hormone receptors, for a period of 5 years.

Five years later the patient consulted for a rash on the level of the red hot breast beyond the infero-internal quadrant, the clinical examination found thick skin with free ganglionic areas. (Figure-1) The mammography had shown an increase in opacity, dense, homogeneous, large in size and with fuzzy limits, without microcalcifications. Ultrasound showed infiltration with thickening of the fatty tissue of the breast, without visible cystic or tumor formation, accompanied by frank.
DISCUSSION

Conservative treatment of breast cancer is a therapeutic option of choice thanks to the generalization of screening and early diagnosis of cancerous lesions.

Radiation therapy is a mandatory step in the conservative treatment of breast cancer, it is often indicated postoperatively. However, a cumulative dose greater than 40 Gy, can induce the development of certain tumors such as angiosarcoma in the long term [1].

Angiosarcoma of the breast was also called hemangiosarcoma, hemangioendotheliosarcoma, hemangioblastoma, Angioblastoma, malignant hemangioendothelioma [2]. The first case was reported by Borman in 1907 [3].

It is a rare tumor representing 0.04% of All malignant breast tumors and 8 to 10% breast sarcomas.

It is a tumor that primarily affects young women during genital activity, especially between 30 and 40 years of age [4]. But, all age groups are concerned, from 13 to 85 years old

Several factors have been incriminated in the genesis of angiosarcomas [5]: exposure to arsenic, to chloroethene, for the hepatic forms; chronic endoluminal irritation by a foreign body for the digestive localizations; chronic lymphedema (Stewart-Treves syndrome) for limb angiomas; pre-existing radiotherapy explains the secondary forms.

The first case of secondary BAS after conservative radio-surgical treatment of breast cancer was reported in 1987 by Body et al., [6] and since then, a hundred new cases have been reported [7].
The radio-induced form occurs, especially, in the elderly woman, with a latency of 29 to 72 months [4], which is the case for our patient.

The incidence of BAS after radiotherapy for breast cancer is estimated between 0.05 and 0.2%.

Cahan et al., proposed four criteria for the diagnosis of radio-induced sarcomas [8]:
- A history of radiotherapy;
- Clinical latency of several years (more than five years);
- The occurrence of sarcoma in the irradiated field;
- Histological confirmation of the sarcomatous nature of the post-radiation lesion.

Our observation met these diagnostic criteria.

BAS is discovered in the majority of cases, following a nodule having a vascular, pulsating character, of black purplish color, bulky with a size often between 2 and 11 cm [11], which increases rapidly in size.

Two clinical signs are pathognomonic of angiosarcoma of the breast: the purplish appearance of the skin next to the tumor and the pulsatile character of the mass [12], which answers our observation.

Axillary lymphadenopathy is exceptional, it does not concern than highly evolved forms [13].

The diagnosis of BAS is essentially based on histological analysis of biopsies performed on a suspicious lesion [9, 10]. Mammography and cytology are most often lacking in this context [9, 10]. Surgery represents the standard treatment for radio-induced BAS [9, 14]. Wide surgical excision is necessary and healthy margins of 2 to 3 cm confirmed by pathology analysis are recommended [15]. This so-called excision surgery poses the problem of skin cover, hence the frequent use of muscle flaps and dermo-epidermal grafts F. Leung et al. [16]. Finally, given the hematogenous spread of these tumors, lymphadenectomy is not indicated [14]

At the end of these histological criteria, two histological classifications were proposed by Donnell [17], and by Merino [18].

Each of these classifications includes three histological types containing the same items; the most currently used is that of Donnell. For tumors difficult to identify on the microscopic study, the vascular nature of the lesion can be confirmed by the immunohistochemical study.

The endothelial markers CD31, CD34, factor VIII, Ulex europaeus agglutinin 1 and vascular endothelial growth factor (VEGF) are typically expressed by angiosarcoma. Only the expression of CD 31 is specific to the latter [5].

The prognosis depends on the histological grade, with a 10-year survival for all forms (primary or secondary) at 76% for well-differentiated grade 1 forms, 20% for grade 3 or poorly differentiated.

The place of adjuvant treatments remains limited in the treatment of post-radiation BAS. To date, neither radiotherapy nor chemotherapy has proven effective [14, 12].

The natural course of radiation-induced angiosarcoma is more or less rapid towards death, which occurs in a metastatic spread after a median survival of 24 months [4].

Recurrences are observed in 77% of cases and after an average delay of 12.8 months [8], which was observed in our patient, a recurrence at 5 months of diagnosis.

Metastases are mainly by the hematogenous route while lymph node involvement is rare [20]. The most frequently invaded organs are the lung, contralateral breast and bone [17].

CONCLUSION
Radiation-induced breast angiosarcoma represents a rare complication of radiotherapy in the context of breast cancer. This tumor has a poor prognosis and its diagnosis must be early because the tumor size on discovery constitutes the major prognostic factor. This diagnosis should be discussed before any change in skin color in a patient with a history of radiation therapy for breast cancer. The positive diagnosis is based on the histological analysis of biopsies performed at the level of the incriminated lesion. The treatment is essentially surgical and consists of a mammectomy with wide margins of excision.

REFERENCES


